The increase in the prevalence of PCOS globally, coupled with a significant rise in healthcare spending on PCOS treatment, are the factors that propel polycystic ovarian syndrome (PCOS) treatment market growth. For instance, approximately 6 million women in the US suffer from PCOS, a common hormone imbalance. It raises the risk of several illnesses, such as endometrial cancer, hypertension, type 2 diabetes, infertility, and stroke. Moreover, the Endocrine Society estimates that the diagnosis and treatment of polycystic ovarian syndrome (PCOS), the most prevalent hormone disorder affecting women of reproductive age, will cost US$ 8 billion nationally in 2020.
Developing novel therapeutics will bring new polycystic ovarian syndrome (PCOS) treatment market trends during the forecast period.
Polycystic ovary syndrome (PCOS) is a common multifactorial endocrine disorder among women. According to the World Health Organization (WHO), PCOS affects an estimated 8–13% of women of reproductive age. Globally, PCOS is the most common cause of anovulation and a leading cause of infertility. Also, ~70% of women affected by PCOS remain undiagnosed. Unhealthy lifestyle diet and some environmental factors can cause PCOS. Obesity is a major risk factor for PCOS, as excess body fat can disrupt hormone levels and insulin sensitivity, leading to the development of the condition. With the global obesity epidemic on the rise, more women are at risk of developing PCOS. According to the World Obesity Atlas 2022 by the World Obesity Federation, by 2030, more than one billion people across the world will be affected by obesity, including 1 in every five women.
Furthermore, the increasing prevalence of PCOS has led to a growing demand for effective treatment options. Various pharmaceutical and non-pharmaceutical PCOS treatments are available to regulate hormone levels, improve insulin sensitivity, and address other underlying factors contributing to PCOS. Thus, the rising prevalence of PCOS among women globally drives the growth of the polycystic ovarian syndrome (PCOS) treatment market.
There is a limited availability of the Food and Drug Administration (FDA)-approved medications specifically designed to address the complex symptoms and underlying hormonal imbalances associated with polycystic ovary syndrome (PCOS). Despite the high prevalence of PCOS and its significant impact on women's health, fertility, and quality of life, there are relatively few pharmaceutical options (off-label drugs) approved by the FDA for the treatment of this condition. The lack of FDA-approved medications presents a challenge for healthcare providers and patients seeking effective and evidence-based PCOS treatments. While off-label use of certain medications such as oral contraceptives, insulin-sensitizing agents, and anti-androgens is common in managing PCOS symptoms, the absence of dedicated therapies limits the ability to address the condition comprehensively. Thus, the limited availability of FDA-approved medications specifically indicated for PCOS restrains the polycystic ovarian syndrome (PCOS) treatment market growth.
The polycystic ovarian syndrome (PCOS) treatment market analysis has been carried out by considering the following segments: product and distribution channel.
By product, the polycystic ovarian syndrome (PCOS) treatment market is segmented into clomiphene citrate, metformin, pioglitazone, oral contraceptives, and others. The metformin segment held the largest market share in 2023. Further, the clomiphene citrate segment is anticipated to register the highest CAGR during the forecast period.
The polycystic ovarian syndrome (PCOS) treatment market, by distribution channel, is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest polycystic ovarian syndrome (PCOS) treatment market share in 2023 and is anticipated to register the highest CAGR during the forecast period.
In terms of geography, the scope of the polycystic ovarian syndrome (PCOS) treatment market report includes North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2023, North America held the largest market share. Growing adoption of the latest medical device technologies, rising prevalence of PCOS, and increasing product innovations by key players contribute to the growing polycystic ovarian syndrome (PCOS) treatment market size in North America. According to the US Department of Health & Human Services, PCOS is a common cause of female infertility in the US, which affects ~6% to 12% (~5 million) of US women of reproductive age. According to the study “Incidence, prevalence, and trends in polycystic ovary syndrome diagnosis,” published in July 2023 in the American Journal of Obstetrics and Gynecology, the incidence rate of PCOS in the US is 42.5 cases per 10,000 people every year. Furthermore, various organizations in the country offer comprehensive evaluation, create awareness, and focus on research related to PCOS. For instance, the UCSF Center for Reproductive Health is actively engaged in research to study the cause of PCOS. Thus, the high prevalence of PCOS and the presence of organizations focused on research and awareness favor the polycystic ovarian syndrome (PCOS) treatment market growth.
The regional trends and factors influencing the Polycystic Ovarian Syndrome (PCOS) Treatment Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Polycystic Ovarian Syndrome (PCOS) Treatment Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 3.46 Billion |
| Market Size by 2031 | US$ 5.26 Billion |
| Global CAGR (2023 - 2031) | 5.4% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Product
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Polycystic Ovarian Syndrome (PCOS) Treatment Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Polycystic Ovarian Syndrome (PCOS) Treatment Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
A few strategic developments by leading players operating in the polycystic ovarian syndrome (PCOS) treatment market, as per the company press releases, are listed below:
Sanofi SA, Merck KGaA, Novartis, Mylan, Takeda Pharmaceutical Company Ltd, Abbott, Teva Pharmaceuticals, Salix Pharmaceuticals Inc, AstraZeneca, and Pfizer Inc are among the prominent companies profiled in the polycystic ovarian syndrome (PCOS) treatment market report. These companies focus on developing new technologies, upgrading existing products, and expanding their geographic presence to meet the growing consumer demand worldwide.
The List of Companies - Polycystic Ovarian Syndrome (PCOS) Treatment Market
Factors such as the increasing prevalence of polycystic ovary syndrome (PCOS) among women globally and increasing government initiatives and support for research in the field of reproductive health propel the polycystic ovarian syndrome (PCOS) treatment market growth. However, the limited availability of FDA-approved medications specifically for PCOS hamper the growth of the market.
Polycystic Ovary Syndrome (PCOS) is a hormonal disorder that causes enlarged ovaries with cysts on their outer edges. Some symptoms of PCOS include excess hair growth, acne, missed or irregular menstrual periods, infertility, and weight gain.
The polycystic ovarian syndrome (PCOS) treatment market was valued at US$ 3.46 billion in 2023.
The polycystic ovarian syndrome (PCOS) treatment market majorly consists of the players, including Sanofi SA, Merck KGaA, Novartis, Mylan, Takeda Pharmaceutical Company Ltd, Abbott, Teva Pharmaceuticals, Salix Pharmaceuticals Inc, AstraZeneca, and Pfizer Inc
The market, by distribution channel, is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest polycystic ovarian syndrome (PCOS) treatment market share in 2023, and it is anticipated to register the highest CAGR during the forecast period.
The polycystic ovarian syndrome (PCOS) treatment market is expected to be valued at US$ 5.26 billion in 2031.
By product, the market is segmented into clomiphene citrate, metformin, pioglitazone, oral contraceptives, and others. The metformin segment held a larger polycystic ovarian syndrome (PCOS) treatment market share in 2023. Further, the clomiphene citrate segment is anticipated to register a faster CAGR during the forecast period.